Drugs / PRGN-3006 T Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03927261 | May 2019 → Aug 2024 overdue | acute myeloid leukemia, myelodysplastic syndrome | Precigen, Inc | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRGN-3006 T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03927261 ↗ |
| Action | Deplete | “Autologous CAR T cells are modified immune cells that have been engineered in the laboratory to specifically target a protein found on tumor cells and kill them.” NCT03927261 ↗ |
| Modality | Cell therapy | “PRGN-3006 (autologous chimeric antigen receptor (CAR) T cells)” NCT03927261 ↗ |
| Route | Intravenous | “following intravenous administration” NCT03927261 ↗ |